In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Purpose Nonadherence to antipsychotic medications is a major obstacle preventing optimal outcomes for patients with schizophrenia. Extended release systems exist in the form of depot injections, but these formulations exhibit several disadvantages. To address these concerns, we previously demonstrated proof of concept for an antipsychotic implant containing risperidone and the biodegradable polymer poly(lactic-co-glycolic) acid (PLGA). Methods We build upon recently published data by utilizing a scalable single-screw extrusion system for the production of PLGA-risperidone implants. Implants were composed of 40% risperidone and 60% PLGA, with varying ratios of lactide to glycolide (50:50, 65:35, 75:25 or 85:15). Risperidone release was assessed in vitro and in vivo in rats, and Level A, B and C correlations (IVIVCs) attempted for all. Bioavailability was verified with locomotor testing Results Level B analysis yielded the greatest correlation between in vitro and in vivo data (R (2) = 0.9425), while Level C yielded the lowest (R (2) = 0.8336). Although, based on qualitative results, a Level A correlation was not achieved, it did produce an R (2) of 0.9261. Locomotor testing demonstrated that peak serum concentrations coincide with significant reductions in activity. Conclusion Data demonstrate the applicability of our modeling system and advance long-term, implantable antipsychotics toward clinical application.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The degradation process for these polymers is mainly through uniform bulk degradation of the matrix where the water penetration into the matrix is higher than the rate of polymer degradation.”
From Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier (2011) · cites this paper as [73]
In the citing paper
“A biphasic curve for drug release as a result of PLGA biodegradation has been shown to display following pattern: (Figure 3) [72–74]”
From Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier (2011) · cites this paper as [73]
In the citing paper
“In the second phase, drug is released progressively through the thicker drug depleted layer.”
From Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier (2011) · cites this paper as [73]
In the citing paper
“Furthermore, the increase of carboxylic end groups as a result of biodegradation autocatalyses the process.”
From Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier (2011) · cites this paper as [73]
In the citing paper
“The biodegradation rate of the PLGA copolymers are dependent on the molar ratio of the lactic and glycolic acids in the polymer chain, molecular weight of the polymer, the degree of crystallinity, and the Tg of the polymer.”
From Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier (2011) · cites this paper as [73]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430 · cited 1×
“However, correlation analysis for oral medications has long been established and widely accepted ( 28 ).”
BackgroundOn the importance and mechanisms of burst release in matrix-controlled drug delivery systems
Huang, X., & Brazel, C. S. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00248-6 · Cited by 1,813 · cited 1×
“Additionally, several manufacturing variables, such as solute size, drug partitioning and drying time, can effect release characteristics ( 39 ).”
BackgroundRobinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
THE UNITED STATES PHARMACOPEIA.
HATCHER, R. A. (1908) · Journal of the American Medical Association · doi:10.1001/jama.1908.25310270030002f · Cited by 1,258
Risperidone in the treatment of schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,193
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
THE UNITED STATES PHARMACOPEIAL CONVENTION
Hirschfelder, A. D. (1930) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1930.02720030050030 · Cited by 1,006
Cost of Relapse in Schizophrenia
Weiden, P. J., & Olfson, M. (1995) · Schizophrenia Bulletin · doi:10.1093/schbul/21.3.419 · Cited by 666
The Economic Burden of Schizophrenia in the United States in 2002
Wu, E. Q., Birnbaum, H. G., Shi, L., Ball, D. E., Kessler, R. C., Moulis, M., & Aggarwal, J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0906 · Cited by 614 · cited 2×
“economic burden of schizophrenia to be $63 billion, a cost that is disproportionately large compared to diseases of similar prevalence ( 2 ,3).”
BackgroundInfluentialGilmer, T. P., Dolder, C. R., Lacro, J. P., Folsom, D. P., Lindamer, L., Garcia, P., & Jeste, D. V. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.692 · Cited by 603
Janssen, P. A., Niemegeers, C. J., Awouters, F., Schellekens, K. H., Megens, A. A., & Meert, T. F. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24408-1 · Cited by 468
Biodegradable Microspheres in Drug Delivery
Okada, H., & Toguchi, H. (1995) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v12.i1.10 · Cited by 397
Melkersson, K. I., Hulting, A.-L., & Brismar, K. E. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1006 · Cited by 299
Effect of drug type on the degradation rate of PLGA matrices
SIEGEL, S., KAHN, J., METZGER, K., WINEY, K., WERNER, K., & DAN, N. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.06.009 · Cited by 208 · cited 2×
“Previous studies have demonstrated similar release profiles with haloperidol, as well as how release profiles vary for different drugs from PLGA matrices (34, 35 ).”
BackgroundMethodSelf-citationThe economic impact of schizophrenia.
Rice, D. P. (1999) · PubMed · Cited by 184
Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia
Halene, T. B., Ehrlichman, R. S., Liang, Y., Christian, E. P., Jonak, G. J., Gur, T. L., Blendy, J. A., Dow, H. C., Brodkin, E. S., Schneider, F., et al. (2009) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2009.00504.x · Cited by 161 · cited 1×
“Testing was performed on days 11, 25, 42, 53, 67, 81, and 95. Single animals were placed in opaque holding containers (19.5′ l×13′ w×15.75′ h) containing fresh bedding, and TopScan recording software (Clever Systems, Inc., Reston, VA) was used to document and measure locomotor activity as previously published ( 37 ).”
MethodInfluentialSelf-citationRelapse and rehospitalization: comparing oral and depot antipsychotics.
Schooler, N. R. (2003) · PubMed · Cited by 141
Tarazi, F. I., Zhang, K., & Baldessarini, R. J. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29589-6 · Cited by 116
Atypical Antipsychotics: Part II Adverse Effects, Drug Interactions, and Costs
Brown, C., Markowitz, J. S., Moore, T. R., & Parker, N. G. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.17216 · Cited by 105
In vivo and in vitro degradation of glycine/DL‐lactic acid copolymers
Schakenraad, J. M., Nieuwenhuis, P., Molenaar, I., Helder, J., Dijkstra, P. J., & Feijen, J. (1989) · Journal of Biomedical Materials Research · doi:10.1002/jbm.820231105 · Cited by 101 · cited 1×
“PLGA is an FDA-approved, biodegradable polymer that is physically strong and highly biocompatible (18, 19 ).”
BackgroundMelkersson, K. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0614 · Cited by 98
[32] Poly(lactic/glycolic acid) biodegradable drug—polymer matrix systems
Kitchell, J. P., & Wise, D. L. (1985) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(85)12034-3 · Cited by 94
The Mean Dissolution Time Depends on the Dose/Solubility Ratio
Rinaki, E., Dokoumetzidis, A., & Macheras, P. E. (2003) · Pharmaceutical Research · doi:10.1023/a:1022652004114 · Cited by 79 · cited 1×
“where M∞ is the asymptotic amount of drug that is dissolved, based on the assumption of complete release ( 36 ).”
BackgroundIyer, S. S., Barr, W. H., & Karnes, H. T. (2006) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.493 · Cited by 73 · cited 1×
“IVIVC data for implantable drug delivery systems ( 27 ).”
BackgroundIn vitro and in vivo demonstration of risperidone implants in mice
Rabin, C., Liang, Y., Ehrlichman, R. S., Budhian, A., Metzger, K. L., Majewski-Tiedeken, C., Winey, K. I., & Siegel, S. J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.08.003 · Cited by 64 · cited 7×
“The in vitro dissolution method has been previously validated using a variety of compounds ( 16 ,17,34,35).”
BackgroundMethodResultInfluentialSelf-citationÖzcanlı, T., Erdoğan, A., Özdemir, S., Onen, B., Özmen, M., Doksat, M. K., & Sonsuz, A. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.03.014 · Cited by 63
Effects of risperidone on glutamate receptor subtypes in developing rat brain
Choi, Y. K., Gardner, M. P., & Tarazi, F. I. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.08.010 · Cited by 62
Surgically Implantable Long-term Antipsychotic Delivery Systems for the Treatment of Schizophrenia
Siegel, S. J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00426-2 · Cited by 53 · cited 3×
“The implants described in this paper could improve adherence by providing a mechanism for patients to make their treatment decisions with their physician during periods of health, rather than having to make a daily choice, which can be particularly difficult during periods of symptom exacerbation ( 17 ).”
BackgroundMethodInfluentialSelf-citationHuang, X. B., Chestang, B. L., & Brazel, C. S. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00433-7 · Cited by 47 · cited 1×
“Several studies have sought to minimize this burst, and it appears that surface extraction and surfacepreferential crosslinking are two particularly effective methods for achieving this goal ( 38 ).”
MethodUtilization of Long-Acting Antipsychotic Medication in Patient Care
Kane, J. M. (2006) · CNS Spectrums · doi:10.1017/s1092852900025852 · Cited by 35
Nasrallah, H. A. (2007) · PubMed · Cited by 34
Pharmacology and Therapeutics: Principles to Practice
Waldman, S. A., & Terzic, A. (2008) · Cited by 33
Effects of risperidone on dopamine receptor subtypes in developing rat brain
Moran‐Gates, T., Grady, C. J., Park, Y. S., Baldessarini, R. J., & Tarazi, F. I. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.10.004 · Cited by 32
Sabel, B. A., Dominiak, P., Häuser, W., During, M. J., & Freese, A. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23191-3 · Cited by 31
Risperidone-induced Hepatotoxicity
Benazzi, F. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979337 · Cited by 28
Hospitalization and Total Medical Costs for Privately Insured Persons with Schizophrenia
Crown, W. H., Neslusan, C. A., Russo, P. A., Holzer, S., Ozminkowski, R., & Croghan, T. W. (2001) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1023/a:1011139215761 · Cited by 26 · cited 1×
“Two major factors contributing to this excessive economic burden are lost income and frequent hospitalizations, secondary to the fact that schizophrenia remains a life-long disorder with a significant rate of relapse in a majority of patients ( 4 ).”
BackgroundNaiker, D. V., Catts, S. V., Catts, V. S., Bedi, K. S., & Bryan‐Lluka, L. J. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.04.048 · Cited by 26
Development of drug delivery systems for use in treatment of narcotic addiction.
Sharon, A. C., & Wise, D. L. (1981) · PubMed · Cited by 25
Metzger, K. L., Shoemaker, J. M., Kahn, J. B., Maxwell, C. R., Liang, Y., Tokarczyk, J., Kanes, S., Hans, M. L., Lowman, A. M., Dan, N. R., et al. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0616-8 · Cited by 21 · cited 2×
“Previous studies have demonstrated similar release profiles with haloperidol, as well as how release profiles vary for different drugs from PLGA matrices ( 34 ,35).”
BackgroundMethodSelf-citationChanging from oral to depot fluphenazine.
YADALAM, K. G., & Simpson, G. M. (1988) · PubMed · Cited by 18
Cited by
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
“This has been demonstrated in both in vivo and in vitro for various drug types and proteins with different polymer ratios [72,73].”
BackgroundSelf-citationFunctionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications
Martins, C., Sousa, F., Araújo, F., & Sarmento, B. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701035 · Cited by 362
PLGA-based nanoparticles: A new paradigm in biomedical applications
Sharma, S., Parmar, A., Kori, S., & Sandhir, R. (2016) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2015.06.014 · Cited by 340
Customizing poly(lactic-co-glycolic acid) particles for biomedical applications
Swider, E., Koshkina, O., Tel, J., Cruz, L. J., de Vries, I. J. M., & Srinivas, M. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.04.006 · Cited by 328
“85:15 means 85% lactic and 15% glycolic acid) [132].”
BackgroundLu, Y., Cheng, D., Niu, B., Wang, X., Wu, X., & Wang, A. (2023) · Pharmaceuticals · doi:10.3390/ph16030454 · Cited by 251
“(B), Comparison of PLGA degradation rates for different monomer ratios [31].”
Background
Metadata
- Authors
- Amann, L. C., Gandal, M. J., Lin, R., Liang, Y., & Siegel, S. J.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Siegel, Steven J.
- Venue
- Pharmaceutical Research
- Published
- 2010-04-27
- Volume
- 27
- Issue
- 8
- Pages
- 1730-1737
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W2036441297
- Cited by
- 99
- References
- 41
- Citations by year
- 2026: 1 · 2025: 11 · 2024: 6 · 2023: 7 · 2022: 2 · 2021: 13 · 2020: 5 · 2019: 6 · 2018: 7 · 2017: 8 · 2016: 5 · 2015: 6 · 2014: 12 · 2013: 4 · 2012: 3
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (R01MH074672)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- in vitro-in vivo correlation, schizophrenia, antipsychotic drug delivery, single-screw extrusion, biodegradable polymer implants, drug release kinetics, bioavailability, locomotor activity, medication non-adherence, sustained drug release
- MeSH terms
- Polylactic Acid-Polyglycolic Acid Copolymer, Animals, Humans, Male, Polyglycolic Acid, Schizophrenia, Antipsychotic Agents, Drug Delivery Systems, Rats, Sprague-Dawley, Risperidone, Lactic Acid, Absorbable Implants, Models, Animal, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.